España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Mitesco
MITI
OTCPK
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$0.4000
0.00
0.00%
At close: -
Get Report
Comment
Mitesco (MITI) Forecast
News
Earnings
Mitesco (MITI) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Mitesco (OTC:MITI) Stock
Mitesco Stock (OTC: MITI)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, June 27, 2022
MITI: Solid progress at clinics; expansion slows until financing completed.
Zacks Small Cap Research
Friday, April 08, 2022
MITI: Mitesco, Inc. – A Great Set-Up for 2022
Zacks Small Cap Research
Thursday, January 06, 2022
MITI: Primary care that puts patients first - Initiating coverage
Zacks Small Cap Research
Thursday, December 09, 2021
5 Penny Stocks Insiders Are Buying
Lisa Levin
Tuesday, November 16, 2021
Health Providers May Need to Understand Patients' Individual Needs To Remain Competitive
Mark Gilman
-
Sponsored
Wednesday, October 13, 2021
These 2 Trends in Healthcare Could Change How You Visit the Doctor
Austin Willson
-
Sponsored
Wednesday, March 07, 2012
Amgen Completes Tender Offer for Outstanding Shares of Micromet
Benzinga
Friday, March 02, 2012
Amgen Announces Initial Results of Tender Offer for Outstanding Shares of Micromet and Commencement of Subsequent Offering
Benzinga
Wednesday, February 15, 2012
Amgen and Micromet Announce Early Termination of HSR Waiting Period for Amgen's Acquisition of Micromet
Benzinga
Thursday, February 02, 2012
Micromet Hits 52-Week High of $10.97
Benzinga
Verastem IPO Launch Captures Investors Attention
Benzinga
Monday, January 30, 2012
Micromet Hits 52-Week High of $10.95
Benzinga
Friday, January 27, 2012
Momentum Trading: These 6 Stocks Are Up More Than 50% Already in 2012
Benzinga
Needham Downgrades Micromet to Hold
Benzinga
Thursday, January 26, 2012
Benzinga's M&A Chatter for Thursday January 26, 2012
Benzinga
Ladenburg Thalmann Downgrades Micromet to Neutral
Benzinga
Piper Jaffray Downgrades Micromet to Neutral
Benzinga
Micromet Up 33% After Acquisition Announcement
Benzinga
Micromet Resumes Trading
Benzinga
Amgen to Acquire Micromet for $11 per Share Totaling $1.16B
Benzinga
Micromet Halted, News Pending
Benzinga
Monday, January 09, 2012
Micromet Signs CRADA with National Cancer Institute to Expand Development of Blinatumomab
Benzinga
Monday, December 12, 2011
Micromet's Blinatumomab Produces Durable Responses in Patients with Relapsed Diffuse Large B Cell Lymphoma Patients
Benzinga
Weekly Homework: In Search Of The Santa Claus Rally (w/ Economic Calendar & Stock Radar)
Benzinga
Monday, November 28, 2011
Micromet Initiates Global Phase 2 Trial of Blinatumomab in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Benzinga
Tuesday, October 25, 2011
Notable Call Options Activity in Micromet
Benzinga
Friday, October 14, 2011
Ladenburg Thalmann Maintains Buy Rating and $7.50 PT on Micromet
Benzinga
Thursday, October 13, 2011
Micromet Obtains FDA Feedback on Registration Strategy for Blinatumomab in Relapsed/Refractory ALL
Benzinga
Wednesday, August 17, 2011
UPDATE: Goldman Sachs Initiates Coverage on Micromet
Benzinga
Goldman Sachs Initiates Micromet At Neutral, $5 PT
Benzinga
Thursday, August 04, 2011
Micromet Reports Q2 EPS $(0.19) vs $(0.21) Es...
Benzinga
Wednesday, July 13, 2011
Edison Comments on Micromet
Benzinga
Benzinga's Top Pre-Market NASDAQ Losers
Benzinga
Monday, July 11, 2011
Benzinga's Top Pre-Market NASDAQ Gainers
Benzinga
Benzinga's Top Pre-Market NASDAQ Gainers
Benzinga
Micromet Announces Solid Tumor BiTE Antibody Collaboration with Amgen; Deal Valued Up to EUR695M
Benzinga
Tuesday, June 14, 2011
Micromet Appoints Ulrich Grau as Chief Operat...
Benzinga
Saturday, June 11, 2011
Promising Leukemia Drug Boosts Micromet
Benzinga
Friday, June 10, 2011
Top Percentage Gainers and Losers as of 2pm 06/10/11
Benzinga
Top Percentage Gainers and Losers as of 12pm 06/10/11
Benzinga
Micromet Trading over 13% Higher on the Session after Positive Clinical Results
Benzinga
Micromet: Study Demonstrates Micromet's Blinatumomab Produces High Single-Agent Activity in Patients with Relapsed Acute Lymphoblastic Leukemia
Benzinga
Tuesday, May 17, 2011
Micromet Announces Data Published in Journal of Clinical Oncology Highlights Significant Activity of Blinatumomab in Patients with Acute Lymphoblastic Leukemia
Benzinga
Wednesday, April 06, 2011
Benzinga's Top Upgrades (CHTR, MITI, WPRT, BCS)
Benzinga
RBC Capital Upgrades Micromet To Outperform, $8 PT
Benzinga
Tuesday, March 29, 2011
Mad Money Lightning Round OT: Cramer Likes ETP And GG (MITI, AT, ETP, NEM, GG, NG)
Benzinga
Friday, March 18, 2011
Japan: The Post-WW2 Rise, the 1980s Peak, and the Decline - A Simple Theory
Benzinga
Thursday, March 03, 2011
Micromet Reports Q4 Loss of $0.17 per share
Benzinga
Wednesday, January 12, 2011
MedImmune and Micromet Announce Initiation of Phase 1 Trial of the CEA BiTE Antibody MEDI-565
Benzinga
Wednesday, January 05, 2011
Piper Jaffray's Favorite Antibody Plays (SGEN, MITI, REGN)
Benzinga
Show More